Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Gain Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BETHESDA, MD., JULY 16, 2026 (GLOBE NEWSWIRE) -- GAIN THERAPEUTICS, INC. (NASDAQ: GANX) (GAIN, OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEADING THE DISCOVERY AND DEVELOPMENT OF THE NEXT GENERATION OF ALLOSTERIC SMALL MOLECULE THERAPIES, TODAY PROVIDED THE FOLLOWING LETTER TO SHAREHOLDERS FROM THE COMPANY'S PRESIDENT AND CEO, GENE MACK: TO OUR VALUED SHAREHOLDERS, AS WE PROGRESS THROUGH 2026 AND LOOK AHEAD TO DELIVERING CONTINUED SIGNIFICANT PROGRESS, I WANT TO THANK YOU FOR YOUR STEADFAST SUPPORT OF GAIN THERAPEUTICS.

GAIN THERAPEUTICS CEO GENE MACK ISSUES LETTER TO SHAREHOLDERS AND PROVIDES OPERATIONAL UPDATE

IND AUTHORIZATION PAVES THE WAY FOR INITIATION OF GT-02287 PHASE 2 CLINICAL DEVELOPMENT IN THE U.S., EXPECTED DURING 3Q26

GAIN THERAPEUTICS RECEIVES FDA CLEARANCE OF IND TO ADVANCE GT-02287 INTO PHASE 2 CLINICAL DEVELOPMENT FOR PARKINSON'S DISEASE

BETHESDA, MD., JUNE 10, 2026 (GLOBE NEWSWIRE) -- GAIN THERAPEUTICS, INC. (NASDAQ: GANX) (GAIN, OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEADING THE DISCOVERY AND DEVELOPMENT OF THE NEXT GENERATION OF ALLOSTERIC SMALL MOLECULE THERAPIES, TODAY ANNOUNCED THAT GENE MACK, PRESIDENT AND CEO, WILL PARTICIPATE IN A VIRTUAL FIRESIDE CHAT AND ONE-ON-ONE MEETINGS AT THE H.C. WAINWRIGHT 7TH ANNUAL NEURO PERSPECTIVES EXPERT SUMMIT, BEING HELD IN A HYBRID FORMAT FROM JUNE 15-16, 2026.

GAIN THERAPEUTICS TO PRESENT AT H.C. WAINWRIGHT 7TH ANNUAL NEURO PERSPECTIVES EXPERT SUMMIT

MDS-UPDRS SCORES REMAINED STABLE AND DURABLE ACROSS OVERALL STUDY POPULATION AFTER 150 DAYS OF TREATMENT WITH GT-02287 DIFFERENTIAL RESPONSE BETWEEN PARTICIPANTS WITH LOW AND HIGH BASELINE GLUSPH CONTINUES, WITH A DIFFERENCE OF 4.8 POINTS IN THE SUM OF MDS-UPDRS PART II AND PART III SCORES BETWEEN THE TWO GROUPS AT DAY 150 MOST COMMON BENEFITS REPORTED BY STUDY PARTICIPANTS INCLUDE MEANINGFUL IMPROVEMENTS IN SPECIFIC FUNCTIONAL AREAS SUCH AS SMELL AND TASTE, SLEEP, AND BALANCE OR GAIT BETHESDA, MD., MAY 26, 2026 (GLOBE NEWSWIRE) -- GAIN THERAPEUTICS, INC. (NASDAQ: GANX) (GAIN, OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEADING THE DISCOVERY AND DEVELOPMENT OF THE NEXT GENERATION OF ALLOSTERIC SMALL MOLECULE THERAPIES, TODAY ANNOUNCED THE PRESENTATION OF AN ORAL PRESENTATION AT THE 3RD INTERNATIONAL GBA1 MEETING 2026, HELD MAY 22-23, 2026, IN PHOENIX, AZ.

GAIN THERAPEUTICS PRESENTS POSITIVE INTERIM DATA FROM PHASE 1B CLINICAL STUDY OF GT-02287 AT 3RD INTERNATIONAL GBA1 MEETING 2026

BETHESDA, MD., MAY 11, 2026 (GLOBE NEWSWIRE) -- GAIN THERAPEUTICS, INC. (NASDAQ: GANX) (GAIN, OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEADING THE DISCOVERY AND DEVELOPMENT OF THE NEXT GENERATION OF ALLOSTERIC SMALL MOLECULE THERAPIES, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2026, AND PROVIDED A CORPORATE UPDATE.

GAIN THERAPEUTICS REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2026 AND PROVIDES CORPORATE UPDATE

BETHESDA, MD., APRIL 24, 2026 (GLOBE NEWSWIRE) -- GAIN THERAPEUTICS, INC. (NASDAQ: GANX) (GAIN, OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEADING THE DISCOVERY AND DEVELOPMENT OF THE NEXT GENERATION OF ALLOSTERIC SMALL MOLECULE THERAPIES, TODAY ANNOUNCED AN ORAL PRESENTATION AT THE 3RD INTERNATIONAL GBA1 MEETING 2026, BEING HELD MAY 22-23, 2026, IN PHOENIX, AZ.

GAIN THERAPEUTICS ANNOUNCES ORAL PRESENTATION AT 3RD INTERNATIONAL GBA1 MEETING 2026

BETHESDA, MD., MARCH 26, 2026 (GLOBE NEWSWIRE) -- GAIN THERAPEUTICS, INC. (NASDAQ: GANX) (GAIN, OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEADING THE DISCOVERY AND DEVELOPMENT OF THE NEXT GENERATION OF ALLOSTERIC SMALL MOLECULE THERAPIES, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2025, AND PROVIDED A CORPORATE UPDATE.

GAIN THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR END 2025 AND PROVIDES CORPORATE UPDATE

BETHESDA, MD., MARCH 19, 2026 (GLOBE NEWSWIRE) -- GAIN THERAPEUTICS, INC. (NASDAQ: GANX) (GAIN, OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEADING THE DISCOVERY AND DEVELOPMENT OF THE NEXT GENERATION OF ALLOSTERIC SMALL MOLECULE THERAPIES, TODAY ANNOUNCED THAT GENE MACK, PRESIDENT AND CEO, WILL PARTICIPATE IN A FIRESIDE CHAT AND ONE-ON-ONE MEETINGS AT THE 38TH ANNUAL ROTH CONFERENCE, BEING HELD MARCH 22-24, 2026, IN DANA POINT, CA.

GAIN THERAPEUTICS TO PRESENT AT THE 38TH ANNUAL ROTH CONFERENCE

ADDITIONAL BIOMARKER ANALYSIS REVEALS HIGHER CSF LEVELS OF DOPA DECARBOXYLASE (DDC  AN EMERGING PD BIOMARKER) AT BASELINE WITH A REDUCTION FOLLOWING 90 DAYS OF DOSING WITH GT-02287 IN INDIVIDUALS WITH HIGH BASELINE CSF GLUCOSYLSPHINGOSINE

GAIN THERAPEUTICS PRESENTS ADDITIONAL CLINICAL AND BIOMARKER DATA FROM PHASE 1B CLINICAL STUDY OF GT-02287 AND PRECLINICAL DATA FROM NOVEL CHEMICAL SERIES AT AD/PD 2026

INTERIM ANALYSIS OF PHASE 1B CLINICAL STUDY OF GT-02287, INCLUDING BIOMARKER AND CLINICAL ENDPOINTS, WILL BE PRESENTED IN ORAL SYMPOSIUM COMPANY REMAINS ON TRACK TO INITIATE PHASE 2 CLINICAL TRIAL OF GT-02287 IN 3Q26 AFTER SUBMITTING ADDITIONAL PRECLINICAL DATA REQUESTED BY FDA IN SUPPORT OF AN IND BETHESDA, MD., MARCH 12, 2026 (GLOBE NEWSWIRE) -- GAIN THERAPEUTICS, INC. (NASDAQ: GANX) (GAIN, OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEADING THE DISCOVERY AND DEVELOPMENT OF THE NEXT GENERATION OF ALLOSTERIC SMALL MOLECULE THERAPIES, TODAY ANNOUNCED PRESENTATIONS AT THE AD/PD  2026 INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASE AND RELATED NEUROLOGICAL DISORDERS, BEING HELD MARCH 17-21, 2026 IN COPENHAGEN, DENMARK.

Gain Therapeutics, Inc.

GANX

Price

Financial Reports

No items found.

Press Releases

Gain Therapeutics, Inc.

GANX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

GANX